Thermo Fisher Scientific (TMO) : Eagle Capital Management reduced its stake in Thermo Fisher Scientific by 5.77% during the most recent quarter end. The investment management company now holds a total of 4,070,082 shares of Thermo Fisher Scientific which is valued at $602,453,538 after selling 249,071 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Thermo Fisher Scientific makes up approximately 2.54% of Eagle Capital Management’s portfolio.
Other Hedge Funds, Including , Geneva Advisors reduced its stake in TMO by selling 367 shares or 3.37% in the most recent quarter. The Hedge Fund company now holds 10,535 shares of TMO which is valued at $1,601,847. Thermo Fisher Scientific makes up approx 0.03% of Geneva Advisors’s portfolio.Wedbush Securities Inc reduced its stake in TMO by selling 33 shares or 1.99% in the most recent quarter. The Hedge Fund company now holds 1,623 shares of TMO which is valued at $237,883. Thermo Fisher Scientific makes up approx 0.04% of Wedbush Securities Inc’s portfolio.Commerce Bank boosted its stake in TMO in the latest quarter, The investment management firm added 7,964 additional shares and now holds a total of 203,017 shares of Thermo Fisher Scientific which is valued at $29,656,723. Thermo Fisher Scientific makes up approx 0.48% of Commerce Bank’s portfolio.Quantitative Investment Management boosted its stake in TMO in the latest quarter, The investment management firm added 23,300 additional shares and now holds a total of 79,200 shares of Thermo Fisher Scientific which is valued at $11,547,360. Thermo Fisher Scientific makes up approx 0.40% of Quantitative Investment Management’s portfolio.
Thermo Fisher Scientific closed down -3.07 points or -2.06% at $145.81 with 26,31,666 shares getting traded on Monday. Post opening the session at $148.77, the shares hit an intraday low of $145.63 and an intraday high of $149.2 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Thermo Fisher Scientific reported $2.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $1.97. The company had revenue of $4491.00 million for the quarter, compared to analysts expectations of $4393.47 million. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 EPS.
Investors should note that on Nov 10, 2016, Thermo Fisher Scientific announced a cash dividend of $0.1500. The company’s management has announced Dec 13, 2016 as the ex-dividend date and fixed the record date on Dec 15, 2016. The payable date has been fixed on Jan 16, 2017.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. Thermo Fisher Scientific was Resumed by Leerink Partners to “Outperform” on Nov 10, 2016. JP Morgan Resumed Thermo Fisher Scientific on Sep 22, 2016 to “Overweight”, Price Target of the shares are set at $180.Thermo Fisher Scientific was Downgraded by Cleveland Research to ” Neutral” on Sep 9, 2016.
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.